Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.

BMC Cancer · 2011 · PMC3125285 · PMID 21669012

Europe PMC DOI

hedged sentence

0.0810

closest p · 1.6× alpha

0.0810

boldest claim

The sentences

a trend toward significancep = 0.081so close (0.05 < p ≤ 0.1)

The interaction test between VEGF -1498 C/T variants and treatment effect, including both bevacizumab-group and control group, suggested that the relation of VEGF -1498 T/T genotype with poor outcome was significantly associated with the effect of bevacizumab in terms of PFS (p = 0.011) and with a trend toward significance with regard to OS (p = 0.081) (Table 5 ).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.